Sanofi and Regeneron provide update on U.S. Phase II/III adaptive-designed trial in hospitalized COVID-19 patients.
Sanofi and Regeneron Pharmaceuticals, Inc., announced the preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating Kevzara (sarilumab) , an interleukin-6 (IL-6) receptor… read more.